Information  X 
Enter a valid email address

Henderson Morley PLC (HML)

  Print      Mail a friend

Monday 03 August, 2009

Henderson Morley PLC

National Institute of Health

RNS Number : 7065W
Henderson Morley PLC
03 August 2009

03 August 2009




('Henderson Morley' 'HM' or 'the Company')


National Institute of Health Grant Application


ThBoard of Henderson Morley, the AIM quoted biotechnology company, is pleased to update the market on previous announcements regarding the Company's Collaborative Research Agreement with the Australian Centre for Vaccine Development ('ACVD')and the submission of a grant application to the US government funded National Institute of Health ('NIH').


The grant application has now been submitted with the goal of securing non-dilutive funding to further develop the Cytomegalovirus ('CMV') Vaccine candidate (part of the PREPS and L-particles vaccine platform). The development of a vaccine for CMV is a priority for the NIH and has been identified as a pathogen that has a significant impact on public health.


Prof Rajiv Khanna, of the ACVD is leading the Australian research, and stated 'Henderson Morley's technology, and the vaccine design expertise of the Queensland Institute of Medical Research (QIMR), Australia, constitutes a unique and powerful approach to the development of a vaccine for CMV. The Poly-L particle approach, patented by Henderson Morley, is unparalleled in the United States


The HM/QIMR approach circumvents the confounding factors that have prevented a functional vaccine in the past. The impact of a successful vaccine would be the prevention of thousands of CMV infections in newborn and immunocompromised patients, and could save millions of dollars in hospitalization costs for the treatment of this deadly and evasive pathogen'' 


Andrew Knight, Executive Chairman, commented:

''We are of course very pleased to be working on this project with the QIMR, which is the largest Medical Research Institute in Australia. The Institute is recognized for world-class research in various areas including immunology, infectious diseases cancer research, genetics and epidemiology.''








HENDERSON MORLEY PLC                                                    0121 442 4600

Andrew Knight, Chairman            


BISHOPSGATE COMMUNICATIONS LTD                                 0207 562 3350

(Public Relations)               

Maxine Barnes
Gemma O'Hara


BREWIN DOLPHIN INVESTMENT BANKING                            0113 241 0126

(Nominated Adviser)

Neil Baldwin


RIVINGTON STREET CORPORATE FINANCE LTD                    020 7562 3380


Monisha Varadan



This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t